Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszcz
Welcome,         Profile    Billing    Logout  
 9 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Klopocka, Maria
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
Bessissow, Talat
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
STATIC, NCT03261206 / 2018-001382-17: Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Active, not recruiting
4
334
Europe, Canada, RoW
5-ASA Withdrawal
Alimentiv Inc., Academic Medical Organization of Southwestern Ontario
Crohn Disease, Remission
06/26
06/26
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
CD-IT, NCT05049525: Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease

Terminated
2
16
Canada
Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally., Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.
Montreal Heart Institute
Crohn's Disease, Inflammatory Bowel Diseases
02/24
02/24
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT01882205: Comparison Between Chromoendoscopy and Virtual Chromoendoscopy (NBI, I-scan, FICE) for Detection of Neoplasia in Long Standing Ulcerative Colitis

Recruiting
N/A
402
Europe, Canada
Virtual chromoendoscopy, Narrow band Imaging (NBI), Fujinon Intelligent Color Enhancement, I-scan, Chromoendoscopy
Universitaire Ziekenhuizen KU Leuven, H.-Hartziekenhuis Roeselare-Menen VZW, Belgium., McGill University, Maastricht University Medical Center, Copenhagen University Hospital at Herlev
Ulcerative Colitis
12/18
11/27
IBDDysplasia, NCT04067778: IBD Neoplasia Surveillance Pilot RCT

Completed
N/A
600
Canada
Intervention Group, Control Group
Ottawa Hospital Research Institute, Health Sciences Centre, Winnipeg, Manitoba, Western University, Canada, University of Toronto, Hamilton Health Sciences Corporation, Thunder Bay Regional Health Sciences Centre, Eastern Health, McGill University Health Centre/Research Institute of the McGill University Health Centre, Providence Health & Services, Royal Jubilee Hospital, University of Alberta, MOUNT SINAI HOSPITAL, Nova Scotia Health Authority
Inflammatory Bowel Diseases, Colonic Neoplasms, Dysplasia
09/22
10/22
NCT03261102: TDM Guided Early Optimization of ADAL in Crohn's Disease

Recruiting
N/A
200
Canada
Adalimumab, Humira
waqqas.afif, AbbVie
Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases
12/23
06/24
NCT05809999: IBD Neoplasia Surveillance RCT

Recruiting
N/A
1952
Canada
Standard colonoscopy with targeted biopsies
Ottawa Hospital Research Institute
Colonic Neoplasms, Inflammatory Bowel Diseases, Dysplasia
12/25
02/26
Manerowski, Marcin
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26

Download Options